By Connor Hart
Nektar Therapeutics named Brian Kotzin its interim chief medical officer, succeeding Mary Tagliaferri, who stepped down from the role citing personal reasons.
Kotzin will assist in the search for a permanent replacement, the San Francisco company said in a Tuesday filing with the Securities and Exchange Commission.
Kotzin has served as a strategic advisor to Nektar since 2023. He has more than 40 years of experience in immunology, as well as development and management experience, the company said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
February 04, 2025 18:03 ET (23:03 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.